Free Trial
NASDAQ:HUMA

Humacyte (HUMA) Stock Price, News & Analysis

Humacyte logo
$2.51 -0.03 (-1.18%)
Closing price 04:00 PM Eastern
Extended Trading
$2.50 -0.01 (-0.40%)
As of 06:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Humacyte Stock (NASDAQ:HUMA)

Key Stats

Today's Range
$2.45
$2.58
50-Day Range
$1.19
$2.77
52-Week Range
$1.15
$9.79
Volume
2.65 million shs
Average Volume
3.83 million shs
Market Capitalization
$389.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.71
Consensus Rating
Buy

Company Overview

Humacyte Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
55th Percentile Overall Score

HUMA MarketRank™: 

Humacyte scored higher than 55% of companies evaluated by MarketBeat, and ranked 467th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Humacyte has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Humacyte has only been the subject of 3 research reports in the past 90 days.

  • Read more about Humacyte's stock forecast and price target.
  • Earnings Growth

    Earnings for Humacyte are expected to grow in the coming year, from ($1.27) to ($0.83) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Humacyte is -3.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Humacyte is -3.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Humacyte's valuation and earnings.
  • Percentage of Shares Shorted

    22.66% of the float of Humacyte has been sold short.
  • Short Interest Ratio / Days to Cover

    Humacyte has a short interest ratio ("days to cover") of 5.8.
  • Change versus previous month

    Short interest in Humacyte has recently decreased by 10.60%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Humacyte does not currently pay a dividend.

  • Dividend Growth

    Humacyte does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    22.66% of the float of Humacyte has been sold short.
  • Short Interest Ratio / Days to Cover

    Humacyte has a short interest ratio ("days to cover") of 5.8.
  • Change versus previous month

    Short interest in Humacyte has recently decreased by 10.60%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Humacyte has a news sentiment score of 0.48. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 10 news articles for Humacyte this week, compared to 10 articles on an average week.
  • Search Interest

    Only 12 people have searched for HUMA on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.
  • MarketBeat Follows

    Only 6 people have added Humacyte to their MarketBeat watchlist in the last 30 days. This is a decrease of -70% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Humacyte insiders have bought more of their company's stock than they have sold. Specifically, they have bought $52,224.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 5.10% of the stock of Humacyte is held by insiders.

  • Percentage Held by Institutions

    44.71% of the stock of Humacyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Humacyte's insider trading history.
Receive HUMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Humacyte and its competitors with MarketBeat's FREE daily newsletter.

HUMA Stock News Headlines

Humacyte Shares Climb on Symvess ECAT Listing - Morningstar
Analysts Set Humacyte, Inc. (NASDAQ:HUMA) Target Price at $11.71
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Humacyte Shares Climb on Symvess ECAT Listing
See More Headlines

HUMA Stock Analysis - Frequently Asked Questions

Humacyte's stock was trading at $5.05 at the beginning of 2025. Since then, HUMA stock has decreased by 50.4% and is now trading at $2.5050.

Humacyte, Inc. (NASDAQ:HUMA) issued its earnings results on Tuesday, May, 13th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.09. The business earned $0.52 million during the quarter, compared to analyst estimates of $0.46 million.
Read the conference call transcript
.

Humacyte's top institutional shareholders include Rowlandmiller & PARTNERS.ADV (0.03%), Wealth Enhancement Advisory Services LLC (0.01%) and Pallas Capital Advisors LLC (0.01%). Insiders that own company stock include Brady W Dougan, Laura E Niklason, Gordon M Binder, Kathleen Sebelius, Dale A Sander, William John Scheessele, Michael T Constantino, Shamik J Parikh and Heather Ledbetter Prichard.
View institutional ownership trends
.

Shares of HUMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Humacyte investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Intel (INTC), JPMorgan Chase & Co. (JPM) and Alphabet (GOOG).

Company Calendar

Last Earnings
5/13/2025
Today
7/10/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:HUMA
CIK
1818382
Fax
N/A
Employees
150
Year Founded
N/A

Price Target and Rating

High Price Target
$25.00
Low Price Target
$4.00
Potential Upside/Downside
+366.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$148.70 million
Pretax Margin
-15,022.44%

Debt

Sales & Book Value

Annual Sales
$1.57 million
Price / Cash Flow
N/A
Book Value
($0.41) per share
Price / Book
-6.12

Miscellaneous

Free Float
147,208,000
Market Cap
$389.35 million
Optionable
Optionable
Beta
1.89
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:HUMA) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners